United States Patent 8,753,665: Claim Scope, Exclusivity, and Bupivacaine Patent Landscape

United States Patent No. 8,753,665 protects polymer-free sustained-release bupivacaine compositions using sucrose acetate isobutyrate, or SAIB, and benzyl alcohol. The core commercial significance is the combination of a bupivacaine free-base payload, a SAIB/benzyl alcohol liquid carrier, and local anesthetic activity lasting at least 24 hours, with dependent claims extending protection to postoperative wound treatment, pouring, topical use, injection, implants, and up to four days of effect.

The patent is materially different from liposomal bupivacaine products such as EXPAREL and from dual-agent products such as ZYNRELEF. It covers a nonpolymeric, in situ depot formulation rather than a liposome or extended-release microsphere.

What does United States Patent 8,753,665 protect?

The patent has two independent composition claims and two independent method claims.

Claim group	Core subject matter	Main limitations
Claims 1-17	Composition and methods using the composition	10%-20% bupivacaine free base, 25%-75% SAIB, 10%-55% benzyl alcohol; at least 24-hour local anesthetic effect
Claims 18-25	Alternative composition definition	10%-20% bupivacaine free base, 25%-75% SAIB, 15%-50% benzyl alcohol; at least 24-hour local anesthetic effect
Claims 26-36	Methods using claim 18 composition	Sustained anesthesia, surgery, postoperative pain, administration by topical use, injection, implant, or pouring

The claims are composition-plus-performance claims. A potentially infringing product must satisfy both the specified formulation architecture and the claimed release or anesthetic-effect limitation.

The central inventive concept is:

Bupivacaine free base as the active pharmaceutical ingredient.
SAIB as the principal viscosity-building and depot-forming component.
Benzyl alcohol as a solvent or carrier component.
A polymer-free formulation capable of producing local anesthesia for at least 24 hours.

How do the independent composition claims differ?

Claims 1 and 18 overlap but are not identical.

Limitation	Claim 1	Claim 18
Bupivacaine free base	10%-20% by weight	10%-20% by weight
SAIB	25%-75% by weight	25%-75% by weight
Benzyl alcohol	10%-55% by weight	15%-50% by weight
Local anesthetic effect	At least 24 hours	At least 24 hours

Claim 18 is narrower for benzyl alcohol because it excludes formulations containing less than 15% or more than 50% benzyl alcohol. Claim 1 has the broader 10%-55% range.

The ranges are not required to total exactly 100% on their face because the claims use overlapping open-ended compositional language and do not expressly exclude additional nonpolymeric ingredients. A formulation must, however, contain the claimed components in the stated proportions relative to total composition weight.

The claims use “about,” which introduces a fact-dependent numerical tolerance. In litigation, the relevant questions would include formulation assay results, manufacturing variation, analytical error, and whether a formulation just outside a numerical endpoint performs substantially the same function in substantially the same way.

What formulations are protected by U.S. Patent 8,753,665?

The patent covers liquid or flowable formulations in which SAIB and benzyl alcohol form a low-viscosity carrier. Claim 14 and claim 23 specify a viscosity of 200 to 6,000 centipoise.

The strongest formulation coverage is directed to products with the following characteristics:

Bupivacaine free base at 10%-20% by weight.
SAIB at 25%-75% by weight.
Benzyl alcohol at 15%-50% by weight to fall within both independent claim sets.
Viscosity of 200-6,000 cP.
No polymer.
Less than approximately 20% bupivacaine release during the first 24 hours.
Local anesthetic activity lasting at least 24 hours and, under dependent claims, 36 hours, 48 hours, or up to four days.

A representative formulation containing 12% bupivacaine, 40% SAIB, and 40% benzyl alcohol would fall within the numerical ranges of claims 1 and 18, assuming the remaining formulation weight consists of permitted ingredients and the performance limitations are met.

Does the patent require a polymer?

No. Claims 15 and 24 expressly state that the composition does not comprise a polymer. This limitation is important because it distinguishes the claimed formulation from polymeric depots based on poly(lactic-co-glycolic acid), polylactic acid, polycaprolactone, or related biodegradable matrices.

The independent claims do not themselves require the absence of a polymer. A formulation containing a polymer could potentially be evaluated under claims 1 or 18 if it otherwise satisfies the claim language. The dependent nonpolymer claims provide narrower and more commercially focused protection.

What administration routes are covered?

The claims cover a broad set of administration modes.

Administration or use	Relevant claims
Topical application	3, 27
Injection	4, 28
Implant	5, 29
Pouring	10, 32
Administration in or adjacent to a surgical wound	6, 7, 30, 31
Surgical inguinal hernia repair	11, 33
Appendectomy	11, 33
Postoperative pain	12, 34
Noninjection administration	16, 36

Claims 16 and 36 create a separate noninjection pathway. They are useful against products administered by pouring, topical application, spraying, dipping, aerosolizing, or a coating applicator, even though injection is separately recited elsewhere.

The claims also cover compositions suitable for topical, systemic, or parenteral administration. That language broadens the intended use environment, but infringement still depends on whether the accused formulation meets the composition and functional limitations.

How strong are the composition claims?

The composition claims have meaningful commercial breadth but several litigation-sensitive limitations.

Strengths

The claims combine structural and functional limitations. A competitor cannot avoid the claims merely by changing the route of administration if it uses the same claimed composition and achieves the required duration of effect.

The claims also cover a platform rather than a single surgical indication. Wound treatment after hernia repair and appendectomy is expressly included, but the broad composition claims are not limited to those procedures.

The polymer-free limitation in claims 15 and 24 can be commercially significant. Many sustained-release drug-delivery systems use polymers, while SAIB-based systems use a small-molecule excipient carrier that can form a viscous depot without a polymer.

Vulnerabilities

The requirement for bupivacaine free base excludes formulations based solely on bupivacaine hydrochloride unless the active species is converted or otherwise present in the claimed free-base form.

The “at least 24 hours” anesthetic-effect requirement may require clinical, pharmacodynamic, or validated in vivo evidence. A formulation within the numerical ranges may still fall outside the claims if it does not provide the required duration.

The “less than about 20%” release limitation in claims 13 and 35 is narrower still. Release testing conditions, sampling intervals, sink conditions, analytical method, and the definition of total releasable bupivacaine would be central to any dispute.

The viscosity range is relevant only to claims 14 and 23. A formulation outside 200-6,000 cP may remain within the broader independent composition claims.

When does U.S. Patent 8,753,665 lose exclusivity?

The patent’s base statutory term is generally calculated as 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers, and any patent-term extension. The published patent records associate the patent family with a 2009 priority date, placing the base term in the 2029 period. The exact enforceable expiration date must be taken from the USPTO patent-term record rather than inferred only from the issue date.[1]

The patent issued on June 17, 2014. Its expiration is therefore not calculated as 20 years from issuance. Patent-term adjustment can extend the term beyond the ordinary 20-year calculation, while a terminal disclaimer can shorten it.

There is no biosimilar exclusivity issue because bupivacaine is a small-molecule active ingredient. Any competitive challenge would proceed through the abbreviated new drug application, 505(b)(2), or ordinary new drug application pathways rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.

What is the Orange Book status of the patent?

The Orange Book relevance depends on the approved product for which the patent is listed. A patent covering a formulation or method of use is potentially listable if it meets FDA listing requirements and is associated with an approved drug product.

For a product such as POSIMIR, the regulatory question is whether the NDA holder listed U.S. Patent 8,753,665 in the FDA Orange Book and whether the listing covers the approved formulation, route, or method of use. The FDA Orange Book should be checked against the specific active approval and supplement because listings can change over time.[2]

The patent is not automatically an Orange Book patent solely because it covers bupivacaine. Listing requires a connection to an approved drug product and compliance with FDA patent-listing rules.

Which companies and products create the main competitive risk?

POSIMIR and SAIB-based bupivacaine

POSIMIR is the product most directly associated with the SAIB-based sustained-release bupivacaine concept. Its formulation and approved use should be compared against the claims on three points:

Bupivacaine form and concentration.
SAIB and benzyl alcohol concentrations.
Duration and site of postoperative analgesia.

If the approved product falls within the claimed ranges, the patent is a core product-facing asset. If the product contains additional ingredients or uses a different concentration profile, the independent claims may still be relevant, but dependent claims may not apply.

EXPAREL

EXPAREL contains liposomal bupivacaine and uses a multivesicular liposome delivery system. Its formulation does not use the SAIB/benzyl alcohol carrier architecture claimed here.[3]

EXPAREL is therefore a competitive substitute but not a close formulation read-on. Its patent estate is directed primarily to liposomal composition, manufacturing, particle structure, and use claims rather than to SAIB depots.

ZYNRELEF

ZYNRELEF combines bupivacaine and meloxicam in a polymeric extended-release solution. Its commercial and patent position is distinct because the product uses a different active combination and delivery technology.[4]

ZYNRELEF may compete for postoperative pain indications, but a formulation based on bupivacaine, meloxicam, and a polymeric carrier would not ordinarily satisfy the SAIB and benzyl alcohol limitations of the ’665 patent.

Conventional bupivacaine products

Immediate-release bupivacaine hydrochloride injections do not generally meet the claimed sustained-release architecture. They remain relevant as potential substitutes and as components of generic postoperative pain protocols, but they present a lower direct infringement risk under the composition claims.

What Paragraph IV challenges could target this patent?

A generic applicant could make a Paragraph IV certification if the patent is listed for an approved reference product and the applicant asserts that the patent is invalid, unenforceable, or not infringed.[5]

The principal challenge theories would likely include:

Lack of written description or enablement. The claims cover broad ranges of three components and multiple administration routes. A challenger could argue that the specification does not support the full breadth of the claimed ranges or all claimed administration modes.
Obviousness. The relevant prior-art combination would likely include bupivacaine depot systems, SAIB-based drug delivery, benzyl alcohol solvents, and sustained local-anesthetic formulations. The challenger would argue that selecting the claimed concentration ranges and duration would have been predictable.
Indefiniteness. Terms such as “about,” “low viscosity,” “sufficient to provide a local anesthetic effect,” and “at least 24 hours” may generate disputes over objective boundaries.
Noninfringement based on active form. A product using bupivacaine hydrochloride rather than bupivacaine free base could avoid a central claim limitation.
Noninfringement based on release profile. A formulation may contain the claimed ingredients but release more than 20% in the first 24 hours or fail to demonstrate the required duration.
Noninfringement based on composition percentages. Small changes in benzyl alcohol or SAIB content could move a product outside the claim ranges, although the term “about” limits the reliability of narrow numerical design-arounds.

What generic launch scenarios exist?

Scenario	Product design	Patent exposure	Commercial timing
Same SAIB platform	Similar bupivacaine/SAIB/benzyl alcohol formulation	High exposure to claims 1 and 18	Launch dependent on patent litigation or settlement
Lower or higher benzyl alcohol	Move outside 10%-55% or 15%-50% range	Potentially reduced literal infringement; doctrine-of-equivalents risk remains	Requires formulation and clinical validation
Bupivacaine hydrochloride	Use salt rather than free base	Potentially avoids free-base limitation	Regulatory and pharmacokinetic comparability required
Polymer depot	Replace SAIB/benzyl alcohol system with polymeric carrier	Lower exposure to ’665 composition claims	May create separate patent and regulatory barriers
Liposomal product	Use liposomal bupivacaine	Generally outside SAIB claims	Competes through a different delivery platform
Immediate-release generic	Conventional bupivacaine injection	Low direct exposure	Does not provide equivalent sustained-release performance

A generic seeking an identical or near-identical SAIB formulation would face greater litigation risk than a company developing a different delivery system. A 505(b)(2) applicant could pursue a modified sustained-release product but would still need to address listed patents and clinical bridging requirements.

What manufacturing and IP barriers exist?

The patent’s practical barrier is not limited to the ingredient list. Commercial replication would require control over:

Bupivacaine free-base particle size and dispersion.
SAIB-to-benzyl-alcohol ratio.
Homogeneity and sedimentation behavior.
Final viscosity and syringeability or pourability.
In situ depot formation at the surgical site.
Initial burst release.
Total release over several days.
Sterility and container-closure compatibility.
Local tissue tolerability.
Reproducibility of postoperative analgesia.

A competitor could avoid literal infringement by changing the carrier system, but the resulting product may lose the desired combination of low viscosity, prolonged residence, and sustained local anesthetic effect. This creates a technical barrier even where the legal claim boundary appears avoidable.

What litigation and settlement issues affect the patent?

A complete litigation assessment requires current PACER, PTAB, USPTO, FDA Orange Book, and assignment records. The claim structure indicates that disputes would likely focus on formulation testing, claim construction of “about,” the meaning of “local anesthetic effect,” and whether the accused product contains bupivacaine free base.

For a Paragraph IV case, the most consequential evidence would be:

Batch composition records.
Certificate-of-analysis data.
Release-testing protocols.
Viscosity measurements.
Clinical efficacy duration.
Manufacturing specifications.
Product labeling and proposed use.
Any formulation-development documents showing intentional movement around the claimed ranges.

No biosimilar settlement framework applies. Any settlement would instead involve generic entry timing, permitted formulation changes, licensed supply, or a covenant not to sue.

Key Takeaways

U.S. Patent 8,753,665 covers polymer-free sustained-release bupivacaine compositions built around SAIB and benzyl alcohol.
Claims 1 and 18 are the principal composition claims.
The core numerical window is 10%-20% bupivacaine free base, 25%-75% SAIB, and 10%-55% or 15%-50% benzyl alcohol.
The claims require at least 24 hours of local anesthetic effect; dependent claims extend to 36 hours, 48 hours, and four days.
The patent covers topical use, injection, implants, pouring, surgical wounds, postoperative pain, hernia repair, and appendectomy.
EXPAREL and ZYNRELEF are commercial competitors but use different delivery technologies.
The base patent term falls in the 2029 period, subject to USPTO patent-term adjustment and other term calculations.
A Paragraph IV challenge would likely focus on obviousness, enablement, indefiniteness, active-form distinctions, and release testing.
The strongest design-around options involve changing the bupivacaine form, moving materially outside the SAIB/benzyl alcohol ranges, or adopting a non-SAIB delivery platform.

Frequently Asked Questions

Is U.S. Patent 8,753,665 a formulation patent or a method-of-use patent?

It is both. Claims 1 and 18 cover compositions. Claims 2-17 and 26-36 cover methods of providing sustained local anesthesia and treating postoperative pain.

Does the patent cover bupivacaine hydrochloride injection?

The independent claims expressly require bupivacaine free base. A conventional bupivacaine hydrochloride injection would generally not satisfy that limitation without evidence that the claimed free-base form is present in the administered composition.

Can a product avoid the patent by using a polymer?

A polymer may avoid dependent claims 15 and 24, which require no polymer. It would not automatically avoid claims 1 or 18 because those independent claims do not expressly exclude polymers.

Does EXPAREL infringe the ’665 patent?

EXPAREL uses a liposomal bupivacaine delivery system rather than the claimed SAIB/benzyl alcohol carrier. On the claim language supplied, it is not a close literal formulation match.

What is the most important technical test for infringement?

The most important tests are formulation composition, bupivacaine chemical form, SAIB and benzyl alcohol percentages, release profile, viscosity where applicable, and proof of local anesthetic activity for at least 24 hours.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,753,665, sustained release local anesthetic compositions.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2023). EXPAREL (bupivacaine liposome injectable suspension) prescribing information. Pacira Pharmaceuticals, Inc.
U.S. Food and Drug Administration. (2023). ZYNRELEF (bupivacaine and meloxicam) extended-release solution prescribing information. Heron Therapeutics, Inc.
U.S. Food and Drug Administration. (2024). Approved drug product and patent certification requirements under the Hatch-Waxman Amendments.

PCT Information
PCT Filed	September 15, 2005	PCT Application Number:	PCT/US2005/032863
PCT Publication Date:	March 30, 2006	PCT Publication Number:	WO2006/033948

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E537844	⤷ Start Trial
Australia	2005287175	⤷ Start Trial
Brazil	PI0515372	⤷ Start Trial
Canada	2581287	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,753,665

Summary for Patent: 8,753,665